Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Beitou District, Taipei, 112, Taiwan (ROC).
School of Medicine, National Yang-Ming University No, 155, Sec.2, Linong Street, Taipei, 112, Taiwan (ROC).
J Neurooncol. 2020 May;147(3):619-631. doi: 10.1007/s11060-020-03456-1. Epub 2020 Mar 28.
The optimal treatment strategy for pediatric atypical teratoid rhabdoid tumor (ATRT) is inconclusive. This study evaluated the prognostic value of early radiotherapy (RT) and high-dose chemotherapy with autologous stem cell rescue (HDC/ASCR) in pediatric ATRT.
This pooled analysis included ATRT patients treated at our institution and from other studies who were identified by a search of the PubMed electronic database. The effect of patient demographics and treatment profiles on progression-free survival (PFS) and overall survival (OS) were analyzed using Cox regression.
Overall, 34 patients from our institution and 436 patients from 35 published studies were included. In multivariable analysis, patients with gross total resection (GTR), early RT (time to RT interval < 2 months), and HDC/ASCR had both better PFS [hazard ratio (HR) 0.46, p[Formula: see text] 0.001; HR 0.64, p = 0.011; and HR 0.51, p = 0.005, respectively] and OS (HR 0.55, p = 0.002; HR 0.48, p = 0.004; and HR 0.42, p < 0.001, respectively). For patients aged < 3 years, both RT and HDC/ASCR were significant favorable factors for PFS (HR 0.32 and 0.46, respectively) and OS (HR 0.40 and 0.36, respectively), while early RT was not prognostic. For patients aged ≥ 3 years, early RT was significantly associated with better PFS (HR 0.51) and HDC/ASCR did not affect PFS, and neither was related to OS.
Both early RT initiation and HDC/ASCR were important components in the treatment of pediatric ATRT. However, the optimal treatment strategies might differ by age.
儿童非典型畸胎样/横纹肌样瘤(ATRT)的最佳治疗策略尚无定论。本研究评估了早期放疗(RT)和自体干细胞挽救高剂量化疗(HDC/ASCR)在儿童 ATRT 中的预后价值。
本汇总分析包括通过检索 PubMed 电子数据库在本机构治疗的 ATRT 患者和来自其他研究的患者。使用 Cox 回归分析患者的人口统计学和治疗特征对无进展生存期(PFS)和总生存期(OS)的影响。
本机构共有 34 例患者,35 项已发表研究共纳入 436 例患者。多变量分析显示,肿瘤全切除(GTR)、早期 RT(RT 时间间隔[Formula: see text]2 个月)和 HDC/ASCR 的患者均具有更好的 PFS [风险比(HR)0.46,p[Formula: see text]0.001;HR 0.64,p=0.011;HR 0.51,p=0.005]和 OS(HR 0.55,p=0.002;HR 0.48,p=0.004;HR 0.42,p[Formula: see text]0.001)。对于年龄[Formula: see text]3 岁的患者,RT 和 HDC/ASCR 对 PFS(HR 0.32 和 0.46)和 OS(HR 0.40 和 0.36)均为显著有利因素,而早期 RT 则无预后意义。对于年龄[Formula: see text]3 岁的患者,早期 RT 与更好的 PFS 显著相关(HR 0.51),HDC/ASCR 对 PFS 无影响,两者均与 OS 无关。
早期 RT 起始和 HDC/ASCR 是儿童 ATRT 治疗的重要组成部分。然而,最佳治疗策略可能因年龄而异。